Home / Pharma Healthcare / United States Hypercholesterolemia Drugs Market Report 2017

United States Hypercholesterolemia Drugs Market Report 2017

  • Id : RNR-158645
  • Category : Pharma Healthcare
  • Publish Date : 17
  • Pages : 114
  • Publisher : S&P Consulting
License Type

Description
In this report, the United States Hypercholesterolemia Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:
    The West
    Southwest
    The Middle Atlantic
    New England
    The South
    The Midwest
with sales (volume), revenue (value), market share and growth rate of Hypercholesterolemia Drugs in these regions, from 2012 to 2022 (forecast).

United States Hypercholesterolemia Drugs market competition by top manufacturers/players, with Hypercholesterolemia Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    AstraZeneca
    Merck
    Pfizer
    Aegerion Pharmaceuticals
    AbbVie
    Sanofi
    Alnylam Pharmaceuticals
    Amarin Corporation
    Amgen
    AtheroNova
    Aurobindo Pharma Limited
    Biocon
    Biospherics
    Bristol-Myers Squibb
    Catabasis Pharmaceuticals
    Daewoong Pharmaceutical
    Daiichi Sankyo
    Lupin Pharmaceuticals

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into
    Statins
    Non-statins
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Hypercholesterolemia Drugs for each application, including
    HMG-CoA reductase inhibitors
    Fibric acid derivatives
    Bile acid sequestrants
    Others